XML 67 R14.htm IDEA: XBRL DOCUMENT v3.20.1
SHARE-BASED COMPENSATION
12 Months Ended
Dec. 31, 2019
SHARE-BASED COMPENSATION  
SHARE-BASED COMPENSATION

NOTE 8—SHARE-BASED COMPENSATION

2015 Equity Incentive Plan

Our board of directors and stockholders have approved and adopted the 2015 Plan, which provided for the grant of incentive stock options, within the meaning of Section 422 of the Code (the Internal Revenue Code), to our employees and any parent and subsidiary corporations’ employees, and for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock and restricted stock units to our employees, directors and consultants and our parent and subsidiary corporations’ employees and consultants. A total of 4,500,000 shares of our common stock were reserved for issuance pursuant to the 2015 Plan. Options granted under the 2015 Plan vest according to the schedule specified in the grant agreements, which is generally a four year period and generally become immediately exercisable upon the occurrence of a change in control, as defined. Upon the 2018 Equity Incentive Plan (the “2018 Plan’) becoming effective in September 2018, no further grants are allowed under the 2015 Plan.

2018 Equity Incentive Plan

Our board of directors and stockholders approved and adopted the 2018 Plan, which became effective upon the Company’s initial public offering in September 2018 and which provides for the grant of incentive stock options, within the meaning of Section 422 of the Code (the Internal Revenue Code), to our employees and any parent and subsidiary corporations’ employees, and for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock and restricted stock units to our employees, directors and consultants and our parent and subsidiary corporations’ employees and consultants. A total of 5,500,000 shares of our common stock, inclusive of the awards previously granted under the 2015 Equity Incentive Plan, are reserved for issuance pursuant to the 2018 Plan. In addition, the number of shares available for issuance under the 2018 Plan will also include an annual increase on the first day of each fiscal year beginning in 2019, equal to 4% of the outstanding shares of common stock as of the last day of our immediately preceding fiscal year. The exercise price of options granted under the plans must at least be equal to the fair market value of our common stock on the date of grant. The term of an incentive stock option may not exceed 10 years, except that with respect to any participant who owns more than 10% of the voting power of all classes of our outstanding stock, the term must not exceed five years and the exercise price must equal at least 110% of the fair market value on the grant date. The administrator will determine the methods of payment of the exercise price of an option, which may include cash, shares or other property acceptable to the administrator, as well as other types of consideration permitted by applicable law. Options granted under the 2018 Plan vest according to the schedule specified in the grant agreements, which is generally over a four year period and generally become immediately exercisable upon the occurrence of a change in control, as defined.

Stock Option Valuation and Restricted Stock Units

During the years ended December 31, 2019 and 2018, stock‑based compensation expenses for stock option grants were $4,581,000 and $1,381,000, respectively, for options granted to employees. During 2019 the expenses were recorded as $933,000 in research and development expense and $3,647,000 in general and administrative expense. During 2018 the expenses were recorded as $276,000 in research and development expense and $1,105,000 in general and administrative expense. Other than $4,581,000 stock option compensation in 2019, another $76,000 restricted stock units, $69,000 in research and development expense and $7,000 in general and administrative expense were recorded in 2019. The total stock based compensation was $4,657,000 in 2019 and $1,381,000 in 2018, respectively.

The assumptions that the Company used to determine the fair value of the stock options granted to employees and directors were as follows, presented on a weighted average basis:

 

 

 

 

 

 

 

    

Year Ended

    

Year Ended

 

 

 

December 31, 2019

 

December 31, 2018

 

 

 

 

 

 

 

Risk-free interest rate

 

1.78

%  

2.89

%  

Expected term (in years)

 

6.3

 

6.3

 

Expected volatility

 

60.6

%  

57.8

%  

Expected dividend yield

 

 —

%  

 —

%  

 

The assumptions that the Company used to determine the fair value of the stock options granted to non‑employees in 2018 were as follows, presented on a weighted average basis:

 

 

 

 

 

 

    

Year Ended

 

 

 

 

December 31, 2018

 

 

 

 

 

 

 

Risk-free interest rate

 

3.00

%

 

Expected term (in years)

 

10.0

 

 

Expected volatility

 

62.7

%

 

Expected dividend yield

 

 —

%

 

 

There were no stock options granted to non-employees in 2019.

The Company recognizes compensation expense for only the portion of awards that vest.

The following table summarizes common stock options issued and outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

    

 

    

 

 

    

 

 

    

Weighted

 

 

 

 

Weighted

 

Aggregate

 

average

 

 

 

 

average

 

intrinsic

 

remaining

 

 

 

 

exercise

 

value

 

contractual

 

 

Options

 

price

 

(in thousands)

 

life (years)

Outstanding and expected to vest at December 31, 2018

 

3,357,873

 

$

7.74

 

$

43,224

 

7.90

Granted

 

648,000

 

$

25.88

 

 

  

 

  

Outstanding and expected to vest at December 31, 2019

 

4,005,873

 

$

10.67

 

$

82,944

 

7.34

Exercisable at December 31, 2019

 

2,495,433

 

$

5.31

 

$

64,738

 

6.41

 

The weighted average grant‑date fair value of stock options granted during the years ended December 31, 2019 and 2018 was $14.92 and $9.58 per share, respectively.

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the Company’s common stock.

As of December 31, 2019 and 2018, we had $15,942,000 and $10,848,000, respectively, of unrecognized compensation related to employee stock options that are expected to vest over a period of 2.72 years in 2019 and 2.82 years in 2018.

 

Restricted Stock Unit Activity

During the year ended December 31, 2019, stock-based compensation for restricted stock unit grants was $76,000. Of this expense $76,000,  $69,000 were recorded in research and development expense and $7,000 in general and administrative expense. There was no stock based compensation for restricted stock units during the year ended December 31, 2018.

The following table summarizes restricted stock units issued and outstanding:

 

 

 

 

 

    

Restricted Stock Units

    

Outstanding and expected to vest at December 31, 2018

 

 —

 

Granted

 

10,296

 

Outstanding and expected to vest at December 31, 2019

 

10,296

 

 

The weighted average fair value of restricted stock units granted during the year ended December 31, 2019 was $23.11.  As of December 31, 2019, we had $163,000 of unrecognized compensation related to employee restricted stock units that are expected to vest over a period of 2.05 years.